Media Coverage

Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others. Take a look at the latest Evaluate and Vantage coverage.

If you have questions about Evaluate or require data and expert insights to help support your editorial content, please see our Media Contacts.

Latest Media Coverage

Financial Times

Big pharma/cancer: the allure of a cure

Such concerns fuelled recent debates over the value of Celgene’s pipeline. The US biotech group has some of the sector’s highest cancer drug revenues, says Evaluate.

Browse the archive

Pharmaceutical Executive

Pharm Exec's Top 50 Companies 2019

In data again provided in partnership with life sciences market intelligence firm Evaluate Ltd, Pfizer ranked first in 2018 prescription drug revenue, totaling $45.3…

FierceBiotech

Biotech's top 10 money raisers of 2018

That hefty average made up for a 10% dip in the number of financing rounds, from 442 to 393, the lowest in a decade, according to a Vantage analysis. The megarounds that…

The Pharma Letter

Look back at pharma news in the week to May 10

Lundbeck has made no secret of its desire for acquisitions, and last week it delivered a takeout of Abide Therapeutics for an initial $250 million, noted Amy Brown on…

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.